PTC Therapeutics Announces Additional Study Of Ataluren In Patients With Advanced Nonsense Mutation Duchenne/Becker Muscular Dystrophy

Please take some time to read an important announcement regarding PTC Therapeutics and Duchenne muscular dystrophy.

Read the Article

*

Related posts:

1. PTC Therapeutics and Genzyme Corporation Announce Preliminary Results from the Phase 2b Clinical Trial Please take some time to read this important announcement: PTC...
2. Systemic Treatment with AVI-4658 Demonstrates RNA Exon Skipping and Dystrophin Protein Expression in Duchenne Muscular Dystrophy Patients Please take some time to read this important announcement regarding...
3. BioMarin Initiates Phase 1 Clinical Study of BMN 195 for Duchenne Muscular Dystrophy Please take some time to read this important press release...
4. Prosensa and GlaxoSmithKline Initiate Development of Four Additional Products under Existing Alliance in Duchenne Muscular Dystrophy Please take a moment to read this important announcement: Prosensa...
5. BioMarin Announces Results for Phase 1 Clinical Study of BMN 195 Contacts: Investors Media Eugenia Shen Susan Berg BioMarin Pharmaceutical Inc....

Related posts brought to you by Yet Another Related Posts Plugin.